These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

515 related articles for article (PubMed ID: 33739346)

  • 21. Clinical Pharmacology of the Antibody-Drug Conjugate Enfortumab Vedotin in Advanced Urothelial Carcinoma and Other Malignant Solid Tumors.
    Tang M; Garg A; Bonate PL; Rosenberg JE; Matsangou M; Kadokura T; Yamada A; Choules M; Pavese J; Nagata M; Tenmizu D; Koibuchi A; Heo N; Wang L; Wojtkowski T; Hanley WD; Poondru S
    Clin Pharmacokinet; 2024 Apr; 63(4):423-438. PubMed ID: 38609704
    [TBL] [Abstract][Full Text] [Related]  

  • 22. EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma.
    Rosenberg JE; Powles T; Sonpavde GP; Loriot Y; Duran I; Lee JL; Matsubara N; Vulsteke C; Castellano D; Mamtani R; Wu C; Matsangou M; Campbell M; Petrylak DP
    Ann Oncol; 2023 Nov; 34(11):1047-1054. PubMed ID: 37678672
    [TBL] [Abstract][Full Text] [Related]  

  • 23. FDA Approval Summary: Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum-Containing Chemotherapy.
    Ning YM; Suzman D; Maher VE; Zhang L; Tang S; Ricks T; Palmby T; Fu W; Liu Q; Goldberg KB; Kim G; Pazdur R
    Oncologist; 2017 Jun; 22(6):743-749. PubMed ID: 28424325
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of enfortumab vedotin in the treatment of advanced urothelial carcinoma: a systematic review and meta-analysis.
    Wang L; Shi G; Zhao G; He W; Cen Z; Xu F
    Anticancer Drugs; 2023 Apr; 34(4):473-478. PubMed ID: 36730481
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Drug approval: Enfortumab vedotin-advanced urothelial carcinoma (which have previously received platinum-containing chemotherapy and immunotherapy)].
    Matte P; Campedel L
    Bull Cancer; 2022; 109(7-8):738-740. PubMed ID: 35606195
    [No Abstract]   [Full Text] [Related]  

  • 26. A phase I study of enfortumab vedotin in Japanese patients with locally advanced or metastatic urothelial carcinoma.
    Takahashi S; Uemura M; Kimura T; Kawasaki Y; Takamoto A; Yamaguchi A; Melhem-Bertrandt A; Gartner EM; Inoue T; Akazawa R; Kadokura T; Tanikawa T
    Invest New Drugs; 2020 Aug; 38(4):1056-1066. PubMed ID: 31444589
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real-world use, dose intensity, and adherence to enfortumab vedotin in locally advanced or metastatic urothelial cancer.
    Mamtani R; Tsingas K; Parikh RB; Elsouda D; Mucha L; Fuldeore R; Hubbard RA
    Urol Oncol; 2024 Jun; 42(6):177.e1-177.e4. PubMed ID: 38503592
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcomes of metastatic urothelial carcinoma following discontinuation of enfortumab-vedotin.
    Curran C; Adib E; Kazakova V; Grivas P; Diamantopoulos LN; Alva AS; Su C; Jain RK; Tandon A; Necchi A; Marandino L; Plastini TM; Merchan JR; Sonpavde G
    Clin Genitourin Cancer; 2022 Feb; 20(1):11-16. PubMed ID: 34503934
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biomarkers of Response to Anti-NECTIN4 Antibody-Drug Conjugate Enfortumab Vedotin in Urothelial Cancer.
    Klümper N; Eckstein M
    Eur Urol Focus; 2024 Mar; 10(2):224-226. PubMed ID: 38631991
    [TBL] [Abstract][Full Text] [Related]  

  • 30. FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma.
    Maguire WF; Lee D; Weinstock C; Gao X; Bulik CC; Agrawal S; Chang E; Hamed SS; Bloomquist EW; Tang S; Pazdur R; Kluetz PG; Amiri-Kordestani L; Suzman DL
    Clin Cancer Res; 2024 May; 30(10):2011-2016. PubMed ID: 38441576
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enfortumab-vedotin use for urothelial carcinoma in two patients on hemodialysis.
    Khosla H; Bhatt S; Wang MJ; Gignac G; Mittal K; Patel J
    J Oncol Pharm Pract; 2024 Jul; 30(5):941-944. PubMed ID: 38470473
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The biology and rationale of targeting nectin-4 in urothelial carcinoma.
    Heath EI; Rosenberg JE
    Nat Rev Urol; 2021 Feb; 18(2):93-103. PubMed ID: 33239713
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and toxicity of antibody-drug conjugates in the treatment of metastatic urothelial cancer: A scoping review.
    Padua TC; Moschini M; Martini A; Pederzoli F; Nocera L; Marandino L; Raggi D; Briganti A; Montorsi F; Necchi A
    Urol Oncol; 2022 Oct; 40(10):413-423. PubMed ID: 35973928
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical practice pattern in patients with advanced urothelial cancer who had progressed on pembrolizumab in the pre-enfortumab vedotin era.
    Kita Y; Ito K; Sano T; Hashimoto K; Mochizuki T; Shiraishi Y; Araki H; Fujiwara M; Kanamaru S; Takahashi T; Hishiki K; Okada T; Ogawa K; Ito M; Kojima T; Nishiyama N; Matsui Y; Nishiyama H; Kitamura H; Kobayashi T
    Int J Urol; 2022 Jul; 29(7):647-655. PubMed ID: 35304776
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The emerging role of antibody-drug conjugates in urothelial carcinoma.
    Lattanzi M; Rosenberg JE
    Expert Rev Anticancer Ther; 2020 Jul; 20(7):551-561. PubMed ID: 32552213
    [TBL] [Abstract][Full Text] [Related]  

  • 36. EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4-Positive Solid Tumors, Including Metastatic Urothelial Carcinoma.
    Rosenberg J; Sridhar SS; Zhang J; Smith D; Ruether D; Flaig TW; Baranda J; Lang J; Plimack ER; Sangha R; Heath EI; Merchan J; Quinn DI; Srinivas S; Milowsky M; Wu C; Gartner EM; Zuo P; Melhem-Bertrandt A; Petrylak DP
    J Clin Oncol; 2020 Apr; 38(10):1041-1049. PubMed ID: 32031899
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A plain language summary exploring a new treatment combination for untreated locally advanced or metastatic urothelial cancer: enfortumab vedotin plus pembrolizumab.
    Hoimes CJ; Flaig TW; Milowsky MI; Friedlander TW; Bilen MA; Gupta S; Srinivas S; Merchan JR; McKay RR; Petrylak DP; Sasse C; Moreno BH; Yu Y; Carret AS; Rosenberg JE
    Future Oncol; 2024 Mar; 20(7):351-360. PubMed ID: 37994649
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of enfortumab vedotin and sacituzumab govitecan in treatment of advanced bladder cancer.
    Hanna KS; Larson S; Nguyen J; Boudreau J; Bulin J; Rolf M
    Am J Health Syst Pharm; 2022 Apr; 79(8):629-635. PubMed ID: 34864835
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enfortumab vedotin and pembrolizumab as new first-line standard for metastatic urothelial cancer.
    Zhu X; Koshkin VS
    Med; 2024 Feb; 5(2):106-108. PubMed ID: 38128535
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enfortumab Vedotin Checks Urothelial Cancer.
    Cancer Discov; 2019 Oct; 9(10):OF1. PubMed ID: 31519705
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.